Ask any community oncology practice administrator to name the number they lose the most sleep over, and it is rarely the denial rate. It is the pending queue: the list of ordered treatments that have been submitted for prior authorization and are simply waiting. In most specialties a pending auth is a billing inconvenience. In oncology it is a patient sitting at home with an untreated malignancy while a payer clock runs. That is why prior authorization turnaround time reduction is not a revenue-cycle nicety in a cancer center; it is patient safety with a dollar sign attached.
The published research is blunt about the scale. Oncologist surveys have found that somewhere between 78 and 94 percent of patients experience a care delay tied to prior authorization, and a meaningful slice of those delays end in patients abandoning or foregoing recommended treatment. When you run the scheduling and financial-clearance operation for an infusion practice, those percentages are not abstract. They are the phone calls your intake team makes to tell a frightened patient that Thursday's chemotherapy has to move to next week because the auth has not cleared.
Why a Pending Auth Becomes an Empty Infusion Chair
Follow the mechanics of a single delayed authorization and you see how a paperwork state converts into a no-show, then into abandonment. The treating oncologist places an order. Financial clearance submits the prior auth. Then the request enters the payer's queue, and your team starts calling to confirm status because you cannot schedule the chair against an unconfirmed auth without gambling on an unauthorized claim that could be a five-figure write-off.
If the confirmation does not land before the scheduled date, the front desk makes a defensive choice: postpone. Nobody wants to run a $9,000 drug and then eat it. So the visit slips a week. For an anxious oncology patient, a slipped week is not neutral. It is a week of wondering whether the cancer is winning, a week of rearranging a caregiver's work schedule, a week of eroding trust that this practice can actually get them treated. Some patients absorb it. Others delay again, seek care elsewhere, or quietly disengage.
flowchart TD
A[Oncologist orders treatment] --> B[Auth submitted to payer]
B --> C{Status confirmed<br/>before visit date}
C -->|Yes| D[Infusion chair fills<br/>revenue captured]
C -->|No| E[Front desk postpones visit]
E --> F[Patient anxiety rises]
F --> G{Patient re-engages}
G -->|Yes| B
G -->|No| H[Treatment abandoned<br/>revenue and outcome lost]The diagram makes the cruel part obvious. The loop between postponement and re-engagement is where patients leak out of the system. Every extra day in the pending queue widens the odds that a patient lands in the abandonment branch instead of the re-engagement branch. Turnaround time is the single variable that governs how many patients you keep in treatment.
The Turnaround Clock Runs on Your Side of the Fax, Not the Payer's
Administrators often assume the delay lives entirely inside the payer. Sometimes it does. But when you time-stamp your own workflow honestly, a large chunk of the turnaround is self-inflicted latency that has nothing to do with the payer's medical-necessity review.
Break a typical oncology auth into its actual time components:
- Assembly and submission lag. The order is placed, but the request does not go out until someone gathers the pathology report, staging, prior therapy history, and the specific J-code regimen. If a document is missing, the payer bounces it and the clock restarts. This is often one to three days of pure internal delay.
- Status-check latency. Once submitted, nobody at the payer calls you when a decision is made. Your team has to go find out. That means staff on hold in payer phone trees, frequently 20 to 40 minutes per call, several times per authorization, to learn a request is "still in review."
- Rework on denials. A denial that could be overturned sits untouched until a staffer has time to read the reason, pull the missing criterion, and resubmit or appeal.
Notice that only the middle of the payer's medical review is genuinely outside your control. The assembly lag, the hold-time latency, and the rework delay are all yours. A serious prior authorization turnaround time reduction program attacks those three, because that is where the recoverable days live. You do not need the payer to get faster to move a patient's treatment date up by three or four days; you need to stop losing those days to hold music and incomplete submissions.
The Dollar Logic of One Abandoned Regimen
It helps to convert the clinical stakes into the financial ones your CFO tracks, because they point in the same direction. Take a mid-sized community oncology practice running, say, 30 infusion chairs across two sites.
A single chemotherapy infusion visit commonly carries several thousand dollars in combined drug acquisition margin and administration revenue. A full regimen might span 6 to 12 visits over several months, plus the imaging and lab work that ride alongside it. When a patient abandons treatment after two delayed auths, you do not lose one visit. You lose the remaining regimen, the surveillance imaging, the follow-up panels, and the survivorship visits that would have followed.
Run the arithmetic on even a conservative abandonment rate. If your practice submits 400 new-treatment auths a month and just 3 percent of those patients abandon after auth-driven delays, that is 12 lost regimens monthly. At a blended contribution figure well into five figures per regimen, the annualized leak runs into seven figures. And that is before you count the empty-chair cost of every postponed visit that did eventually happen: an infusion chair that sits idle Thursday because an auth slipped is capacity you can never resell, since chair-hours do not carry over.
This is why turnaround reduction is not a soft, quality-of-life initiative. It is one of the highest-yield revenue-cycle levers a cancer center has, precisely because the downstream value of each retained patient is so large. The math on where that recovered margin justifies operational investment is laid out on our /pricing page, but the headline is simple: keeping a handful of regimens per month from abandoning pays for the tooling many times over.
Where Voice AI and Real-Time Eligibility Compress the Timeline
The two internal delays worth automating first are the ones that consume the most staff hours for the least clinical judgment: verifying eligibility before submission, and chasing status after it. Neither requires a clinician; both currently burn your most experienced auth coordinators.
Real-time eligibility and benefits checks close the assembly gap. Before a request leaves the building, the system confirms the patient's plan is active, the drug is on the covered pathway, and the plan actually requires the auth in the first place, so you are not submitting requests that bounce for missing or wrong information. That alone removes a category of one-to-three-day restart loops.
Status-checking is the piece that voice AI changes most dramatically. Instead of a coordinator dialing a payer, navigating the IVR, and waiting on hold to hear "still pending," an AI voice agent places those calls, works through the phone tree, retrieves the current authorization status or reference number, and writes it straight back into your worklist. The agent can do this across dozens of open auths in parallel, at 6 a.m. before the queue backs up, without a single staffer on hold. Using voice AI to call insurance for prior auth status turns a full-time hold-music job into a background process, and it surfaces approvals hours or days earlier than a human team working a call list sequentially would.
flowchart LR
A[Open auth worklist] --> B[Voice AI calls payer]
B --> C[Reads back status<br/>and reference number]
C --> D{Approved}
D -->|Yes| E[Schedule infusion<br/>notify patient]
D -->|No| F[Route to appeal team<br/>with denial reason]
F --> G[Denial appeal service<br/>rework and resubmit]When a status check comes back as a denial, the same pipeline hands it to your appeal workflow with the reason already captured, so a prior authorization denial appeal service or your in-house appeals staff starts from a complete picture instead of a cold read. The full set of these capabilities, from eligibility checks to the AI status agent to the reminder engine that keeps confirmed patients from no-showing, is detailed on our /features page. The point is not to replace your auth team's clinical judgment. It is to stop spending that judgment on hold time.
What an Oncology Auth Team Should Measure Starting Monday
If you want to run turnaround reduction as an operational program rather than a slogan, instrument it. A handful of metrics tell you whether you are actually moving patients into chairs faster.
- Order-to-submission hours. The clock from the oncologist's order to a clean request leaving your office. This is your assembly lag, and it is the most controllable number on the list.
- Submission-to-decision days, split by payer. Track it per payer, because your Medicare Advantage plans and your commercial plans behave nothing alike, and knowing which payer sits on requests tells you where to escalate.
- Auth-related postponement rate. The share of scheduled infusion visits that get moved because the auth was not confirmed. This is your leading indicator for abandonment.
- Abandonment-after-delay rate. The share of patients who never re-engage after an auth-driven postponement. This is the number that ties directly to both harm and lost margin.
- Staff hold-time hours per week. Because that is the cost you are converting into automation, and watching it fall is how you prove the program is working.
Multi-touch auth workflows, where three or more staff each handle a piece of the same request, tend to inflate every one of these numbers through handoff delay, which is worth auditing alongside the timeline itself.
Closing the Gap Between Order and Chair
The uncomfortable truth for an oncology practice is that the sickest patients are the ones most exposed to your slowest process. A delayed auth in dermatology means a patient waits for a biopsy result. A delayed auth in oncology means a tumor gets more time. That is the moral weight behind turnaround reduction, and it happens to line up perfectly with the financial case: the same days you shave off the pending queue are the days that keep patients in treatment and chairs full.
Start by timing your own workflow before you blame the payer. Measure order-to-submission, split decision time by payer, and count the hours your team loses on hold. Then automate the two steps that need no clinician: verify eligibility before you submit, and let a voice agent chase status so your coordinators can work denials and talk to patients instead of waiting in a phone tree. Get those days back, and the empty Thursday chair fills, the frightened patient gets treated on schedule, and the regimen you would have lost stays on the calendar.